查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1802954

全球腎上腺危機管理市場：預測至 2032 年－按治療類型、給藥途徑、病患細分、分銷管道、最終用戶和地區進行分析

Adrenal Crisis Management Market Forecasts to 2032 - Global Analysis By Treatment Type, Route of Administration, Patient Group, Distribution Channel, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，全球腎上腺危像管理市場預計在 2025 年達到 26 億美元，到 2032 年將達到 44 億美元，預測期內的複合年成長率為 7.5%。

腎上腺危象的處理包括立即靜脈或肌肉注射Hydrocortisone，隨後用等滲鹽水快速進行液體復甦。對於面臨急性壓力源（例如感染、創傷或手術）的腎上腺功能不全患者來說，這是一個至關重要的通訊協定。及時介入可預防休克、器官衰竭和死亡。持續使用Hydrocortisone並接受內分泌科醫生的監測至關重要，直到臨床完全康復。

根據美國衛生研究院 (NIH) 的數據，腎上腺危症）的盛行率約為每百萬人 110-144 例。

自體免疫疾病盛行率不斷上升

自體免疫疾病（例如愛迪生氏症、先天性腎上腺增生症增生和原發性腎上腺功能不全）的盛行率不斷上升，大大推動了腎上腺危像管理市場的擴張。醫療專業人員診斷能力的提高和意識提升有助於早期發現。老年人口的成長，特別是那些容易罹患內分泌失調的老年人口，進一步刺激了市場需求。此外，慢性壓力、環境毒素和飲食變化等生活方式因素與自體免疫疾病的盛行率上升有關。這種流行病學趨勢需要強力的治療性介入和緊急管理通訊協定，這為專門從事腎上腺危象預防和治療解決方案的製藥公司和醫療設備製造商創造了巨大的市場機會。

醫療費用高昂

緊急Hydrocortisone注射、持續荷爾蒙補充療法以及專業監測設備都需要大量的醫療費用。腎上腺功能不全的慢性性質使得患者需要終生治療方法，從而對患者和醫療保健系統帶來累積的成本壓力。此外，某些治療方法和診斷方法的保險覆蓋範圍有限，這加劇了經濟挑戰。新興市場的經濟負擔尤其突出，這些市場的醫療基礎設施和報銷政策仍然不足，這可能會限制先進腎上腺危機管理解決方案的市場滲透率以及針對不同患者群體的採用。

用於患者監測和依從性的數位健康解決方案

具有皮質醇監測功能的穿戴式設備可實現即時生理追蹤，並促進主動危機預防。智慧型手機應用程式提供服藥提醒、壓力水平監測和緊急應變通訊協定，從而改善患者預後。遠端醫療平台將患者與內分泌科醫生聯繫起來，進行遠距諮詢和藥物調整。此外，人工智慧演算法可以根據患者資料模式預測危機發作，從而實現預防性干預。新冠疫情加速了數位醫療的普及，為創新監測解決方案創造了良好的市場環境，這些解決方案可增強病患安全性，同時降低醫療成本和住院率。

新產品和套件的報銷障礙

監管機構要求在核准報銷之前，提供大量臨床證據來證明成本效益和安全性。保險公司通常優先考慮成熟的治療方法而非創新治療方法，這限制了先進治療方法的可近性。漫長的報銷核准時間會延遲產品的商業化和打入市場策略。此外，不同地區和醫療體系的報銷政策差異也使全球市場滲透變得複雜。這些挑戰，特別影響急救注射器和新型診斷試劑套件，可能會阻礙創新技術的採用，並限制患者獲得尖端腎上腺危像管理技術的機會，儘管這些技術可能具有潛在的臨床益處。

COVID-19的影響：

COVID-19疫情對腎上腺危機管理市場造成了重大衝擊，導致醫療服務中斷、常規監測預約延誤。腎上腺功能不全患者更容易受到感染疾病，需要加強預防措施並制定壓力類固醇給藥方案。此外，供應鏈中斷影響了藥物可得性，尤其是Hydrocortisone可的松製劑。隨著醫療服務提供者尋求替代性諮詢方法，遠端醫療的採用激增，數位健康解決方案的整合也加速發展。此外，疫情凸顯了緊急準備的重要性，推動了對用於危機管理的家用監測設備和自我管理套件的需求。

預測期內，糖皮質激素治療領域預計將成為最大的市場

糖皮質激素治療領域預計將在預測期內佔據最大的市場佔有率，這得益於其作為腎上腺功能不全和危象預防的主要治療手段的根本性作用。Hydrocortisone仍然是荷爾蒙補充療法的黃金標準，其有效性和安全性已得到大量臨床證據的支持。此外，該領域提供多種劑型，包括口服片劑、注射液和緊急自動注射器，以滿足不同患者的需求。成熟的治療方案和醫生對糖皮質激素給藥的熟悉程度，有助於其維持市場領先地位。

預計小兒科在預測期內的複合年成長率最高

由於兒童先天性腎上腺疾病的認知度和診斷率不斷提高，預計小兒科領域將在預測期內達到最高成長率。先天性腎上腺增生症和原發性腎上腺功能不全等早發性疾病需要根據兒童生理狀況量身定做的專門治療方法。此外，改進的新生兒篩檢計畫實現了早期發現，從而增加了對適合其年齡的治療方案和監測設備的需求。兒科內分泌科醫生和基層醫療醫生對腎上腺危症識別意識的不斷提高也使兒科領域受益。此外，家長對兒科腎上腺綜合護理的認知和支持不斷提高，也進一步推動了該領域的擴張。

比最大的地區

在預測期內，北美預計將佔據最大的市場佔有率，這得益於其先進的醫療基礎設施、全面的保險覆蓋以及強大的藥物研發能力。該地區成熟的內分泌治療中心和專業的腎上腺功能不全診所為患者照護。此外，強大的法律規範確保了產品品質和安全，同時也促進了創新技術的採用。高昂的醫療支出和病患意識層級支持著先進的治療方案和複雜的監測技術。政府推動的罕見疾病研究措施以及患者權益組織的發展也促進了市場的持續成長。

複合年成長率最高的地區：

預計亞太地區將在預測期內見證最高的複合年成長率，這得益於醫療基礎設施的擴大、診斷能力的提高以及醫療專業人員疾病意識的不斷增強。日益成長的經濟繁榮推動了醫療支出的增加，使人們能夠獲得先進的治療方法。此外，政府促進醫療服務和保險覆蓋的措施也在推動市場滲透。該地區患者人數眾多，內分泌疾病的流行病學監測也得到改善。內分泌學和急診醫學的醫生培訓計畫的增加正在提高危機意識和管理能力。數位醫療技術的採用和遠端醫療的整合進一步推動了亞太地區多元化醫療體系市場快速擴張。

給藥途徑

  • 靜脈注射
  • 肌肉注射（IM）
  • 口服
  • 皮下給藥

免費客製化服務

此報告的訂閱者可以從以下免費自訂選項中選擇一項：

  • 公司簡介
    • 對最多三家其他公司進行全面分析
    • 主要企業的SWOT分析（最多3家公司）
  • 區域分類
    • 根據客戶興趣對主要國家進行的市場估計、預測和複合年成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第 2 章 簡介

  • 概述
  • 相關利益者
  • 分析範圍
  • 分析方法
    • 資料探勘
    • 數據分析
    • 數據檢驗
    • 分析方法
  • 分析材料
    • 主要研究資料
    • 二手研究資訊來源
    • 先決條件

第3章市場走勢分析

  • 驅動程式
  • 抑制因素
  • 市場機會
  • 威脅
  • 最終用戶分析
  • 新興市場
  • COVID-19的感染疾病

第4章 波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代產品的威脅
  • 新參與企業的威脅
  • 企業之間的競爭

5. 全球腎上腺危機管理市場（依治療類型）

  • 糖皮質激素治療
    • Hydrocortisone（靜脈注射/肌肉注射）
    • 地塞米松
    • 其他糖皮質激素
  • 鹽皮質激素療法（ludrocortisone）
  • 體液/電解質補充療法
  • 輔助性治療

6. 全球腎上腺危機管理市場（依給藥途徑）

  • 靜脈注射（IV）
  • 肌肉注射（IM）
  • 口服
  • 皮下

7. 全球腎上腺危機管理市場（依患者細分）

  • 成人
  • 孩子們
  • 老年人
  • 新生

8. 全球腎上腺危機管理市場（依通路）

  • 醫院藥房
  • 零售藥局
  • 網路藥局
  • 專業藥品經銷商

9. 全球腎上腺危機管理市場（依最終用戶）

  • 醫院
  • 緊急護理中心
  • 專科診所
  • 居家醫療
  • 門診手術中心
  • 其他最終用戶

10. 全球腎上腺危機管理市場（按地區）

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲地區

第11章：主要趨勢

  • 合約、商業夥伴關係和合資企業
  • 企業合併與收購（M&A）
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第12章 公司概況

  • Eton Pharmaceuticals
  • Takeda Pharmaceutical Company Limited
  • Pfizer Inc.
  • Antares Pharma
  • Sandoz International GmbH
  • Halozyme Therapeutics
  • Novartis AG
  • Teva Pharmaceutical Industries Ltd.
  • GlaxoSmithKline plc
  • AbbVie Inc.
  • Mylan NV
  • Ferring Pharmaceuticals
  • Hikma Pharmaceuticals
  • Sun Pharmaceutical Industries Ltd.
  • Cipla Ltd.
  • Sanofi SA
  • Bayer AG
  • AstraZeneca plc
  • Amneal Pharmaceuticals
  • Endo International plc
Product Code: SMRC30480

According to Stratistics MRC, the Global Adrenal Crisis Management Market is accounted for $2.6 billion in 2025 and is expected to reach $4.4 billion by 2032 growing at a CAGR of 7.5% during the forecast period. Adrenal crisis management involves the immediate administration of intravenous or intramuscular hydrocortisone, followed by rapid fluid resuscitation using isotonic saline. It is a critical protocol for patients with adrenal insufficiency facing acute stressors such as infection, trauma, or surgery. Timely intervention prevents shock, organ failure, and death. Continued hydrocortisone dosing and endocrinologist oversight are essential until full clinical recovery is achieved.

According to the National Institutes of Health (NIH), adrenal insufficiency, the primary risk factor for adrenal crisis, has a prevalence of approximately 110-144 cases per million population.

Market Dynamics:

Driver:

Rising prevalence of autoimmune disorders

The escalating incidence of autoimmune conditions such as Addison's disease, congenital adrenal hyperplasia, and primary adrenal insufficiency significantly drives the adrenal crisis management market expansion. Improved diagnostic capabilities and enhanced awareness among healthcare professionals contribute to earlier detection rates. The growing geriatric population, particularly susceptible to endocrine disorders, further amplifies market demand. Moreover, lifestyle factors, including chronic stress, environmental toxins, and dietary changes, have been linked to increased autoimmune disorder prevalence. This epidemiological trend necessitates robust therapeutic interventions and emergency management protocols, thereby creating substantial market opportunities for pharmaceutical companies and medical device manufacturers specializing in adrenal crisis prevention and treatment solutions.

Restraint:

High cost of treatment

Emergency hydrocortisone injections, continuous hormone replacement therapy, and specialized monitoring equipment require considerable healthcare expenditure. The chronic nature of adrenal insufficiency demands lifelong treatment regimens, creating cumulative cost pressures for patients and healthcare systems. Moreover, limited insurance coverage for certain therapeutic options and diagnostic procedures exacerbates affordability challenges. The economic strain is particularly pronounced in developing regions where healthcare infrastructure and reimbursement policies remain inadequate, potentially limiting market penetration and adoption of advanced adrenal crisis management solutions across diverse patient populations.

Opportunity:

Digital health solutions for patient monitoring and adherence

Wearable devices equipped with cortisol monitoring capabilities enable real-time physiological tracking, facilitating proactive crisis prevention. Smartphone applications provide medication reminders, stress level monitoring, and emergency response protocols, improving patient outcomes. Telemedicine platforms connect patients with endocrinologists for remote consultations and dosage adjustments. Moreover, artificial intelligence algorithms can predict crisis episodes based on patient data patterns, enabling preventive interventions. The COVID-19 pandemic has accelerated digital health adoption, creating favorable market conditions for innovative monitoring solutions that enhance patient safety while reducing healthcare costs and hospital readmissions.

Threat:

Reimbursement hurdles for newer products and kits

Regulatory agencies require extensive clinical evidence demonstrating cost-effectiveness and safety profiles before approving coverage. Insurance providers often prioritize established treatments over innovative solutions, limiting access to advanced therapeutic options. The lengthy reimbursement approval timeline delays product commercialization and market entry strategies. Moreover, varying reimbursement policies across different regions and healthcare systems complicate global market penetration efforts. These challenges particularly affect emergency injection devices and novel diagnostic kits, potentially hindering innovation adoption and restricting patient access to cutting-edge adrenal crisis management technologies despite their clinical benefits.

Covid-19 Impact:

The COVID-19 pandemic significantly impacted the adrenal crisis management market through disrupted healthcare services and delayed routine monitoring appointments. Patients with adrenal insufficiency faced increased infection vulnerability, necessitating enhanced precautionary measures and stress-dose steroid protocols. Additionally, supply chain disruptions affected medication availability, particularly hydrocortisone products. Telemedicine adoption surged as healthcare providers sought alternative consultation methods, accelerating digital health solution integration. Moreover, the pandemic highlighted the importance of emergency preparedness, driving demand for home-based monitoring devices and self-administration kits for crisis management.

The glucocorticoid therapy segment is expected to be the largest during the forecast period

The glucocorticoid therapy segment is expected to account for the largest market share during the forecast period due to its fundamental role as the primary treatment modality for adrenal insufficiency and crisis prevention. Hydrocortisone remains the gold standard for hormone replacement therapy, with extensive clinical evidence supporting its efficacy and safety profile. Additionally, the segment encompasses various formulations, including oral tablets, injectable solutions, and emergency auto-injectors, catering to diverse patient needs. The well-established treatment protocols and physician familiarity with glucocorticoid administration contribute to sustained market leadership.

The paediatrics segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the pediatrics segment is predicted to witness the highest growth rate due to increasing recognition and diagnosis of congenital adrenal disorders in children. Early-onset conditions such as congenital adrenal hyperplasia and primary adrenal insufficiency require specialized treatment approaches tailored to pediatric physiology. Additionally, improved neonatal screening programs enable earlier detection, driving demand for age-appropriate therapeutic formulations and monitoring devices. The segment benefits from enhanced awareness among pediatric endocrinologists and primary care physicians regarding adrenal crisis recognition. Moreover, growing parental awareness and advocacy for comprehensive pediatric adrenal care further accelerates segment expansion.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share through advanced healthcare infrastructure, comprehensive insurance coverage, and robust pharmaceutical research capabilities. The region benefits from established endocrinology treatment centers and specialized adrenal insufficiency clinics providing expert patient care. Additionally, strong regulatory frameworks ensure product quality and safety while facilitating innovation adoption. High healthcare expenditure and patient awareness levels support premium treatment options and advanced monitoring technologies. Government initiatives promoting rare disease research and patient advocacy organizations contribute to sustained market growth.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, driven by expanding healthcare infrastructure, increasing diagnostic capabilities, and rising disease awareness among healthcare professionals. Growing economic prosperity enables enhanced healthcare spending and access to advanced therapeutic options. Additionally, government initiatives promoting healthcare accessibility and insurance coverage expansion facilitate market penetration. The region benefits from a large patient population and improving epidemiological surveillance systems for endocrine disorders. Rising physician training programs in endocrinology and emergency medicine enhance crisis recognition and management capabilities. The digital health technology adoption and telemedicine integration further support rapid market expansion across diverse Asia Pacific healthcare systems.

Key players in the market

Some of the key players in Adrenal Crisis Management Market include Eton Pharmaceuticals, Takeda, Pfizer, Antares Pharma, Sandoz, Halozyme, Novartis, Teva, GSK, AbbVie, Mylan, Ferring, Hikma, Sun Pharma, Cipla, Sanofi, Bayer, AstraZeneca, Amneal, and Endo International.

Key Developments:

In July 2025, Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, has launched Morphine Sulfate Injection, USP, in 2mg/mL and 4mg/mL doses in the US. The product has been launched in a prefilled syringe form and is indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.

In January 2022, Antares Pharma, Inc. a specialty pharmaceutical company, today announced positive results from a Phase I study for ATRS-1902 for adrenal crisis. The positive results support the advancement of the ATRS-1902 development program to a pivotal clinical study for the treatment of acute adrenal insufficiency, known as adrenal crisis, in adults and adolescents, using our Vai(TM) novel proprietary rescue pen platform to deliver a liquid stable formulation of hydrocortisone.

In June 2021, Eton Pharmaceuticals, Inc the U.S. marketer of ALKINDI SPRINKLE(R), a treatment for adrenocortical insufficiency in pediatric patients, today announced that it has acquired U.S. and Canadian rights to Crossject's ZENEO(R) hydrocortisone needleless autoinjector, which is under development as a rescue treatment for adrenal crisis.

Treatment Types Covered:

  • Glucocorticoid Therapy
  • Mineralocorticoid Therapy (Fludrocortisone)
  • Fluid & Electrolyte Replacement Therapy
  • Adjunctive Therapies

Route of Administrations:

  • Intravenous (IV)
  • Intramuscular (IM)
  • Oral
  • Subcutaneous

Patient Groups Covered:

  • Adults
  • Pediatrics
  • Geriatrics
  • Neonates

Distribution Channels Covered:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Specialty Drug Distributors

End Users Covered:

  • Hospitals
  • Emergency Care Centers
  • Specialty Clinics
  • Home Care Settings
  • Ambulatory Surgical Centers
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Adrenal Crisis Management Market, By Treatment Type

  • 5.1 Introduction
  • 5.2 Glucocorticoid Therapy
    • 5.2.1 Hydrocortisone (IV/IM)
    • 5.2.2 Dexamethasone
    • 5.2.3 Other Glucocorticoids
  • 5.3 Mineralocorticoid Therapy (Fludrocortisone)
  • 5.4 Fluid & Electrolyte Replacement Therapy
  • 5.5 Adjunctive Therapies

6 Global Adrenal Crisis Management Market, By Route of Administration

  • 6.1 Introduction
  • 6.2 Intravenous (IV)
  • 6.3 Intramuscular (IM)
  • 6.4 Oral
  • 6.5 Subcutaneous

7 Global Adrenal Crisis Management Market, By Patient Group

  • 7.1 Introduction
  • 7.2 Adults
  • 7.3 Pediatrics
  • 7.4 Geriatrics
  • 7.5 Neonates

8 Global Adrenal Crisis Management Market, By Distribution Channel

  • 8.1 Introduction
  • 8.2 Hospital Pharmacies
  • 8.3 Retail Pharmacies
  • 8.4 Online Pharmacies
  • 8.5 Specialty Drug Distributors

9 Global Adrenal Crisis Management Market, By End User

  • 9.1 Introduction
  • 9.2 Hospitals
  • 9.3 Emergency Care Centers
  • 9.4 Specialty Clinics
  • 9.5 Home Care Settings
  • 9.6 Ambulatory Surgical Centers
  • 9.7 Other End Users

10 Global Adrenal Crisis Management Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Eton Pharmaceuticals
  • 12.2 Takeda Pharmaceutical Company Limited
  • 12.3 Pfizer Inc.
  • 12.4 Antares Pharma
  • 12.5 Sandoz International GmbH
  • 12.6 Halozyme Therapeutics
  • 12.7 Novartis AG
  • 12.8 Teva Pharmaceutical Industries Ltd.
  • 12.9 GlaxoSmithKline plc
  • 12.10 AbbVie Inc.
  • 12.11 Mylan N.V.
  • 12.12 Ferring Pharmaceuticals
  • 12.13 Hikma Pharmaceuticals
  • 12.14 Sun Pharmaceutical Industries Ltd.
  • 12.15 Cipla Ltd.
  • 12.16 Sanofi S.A.
  • 12.17 Bayer AG
  • 12.18 AstraZeneca plc
  • 12.19 Amneal Pharmaceuticals
  • 12.20 Endo International plc

List of Tables

  • Table 1 Global Adrenal Crisis Management Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Adrenal Crisis Management Market Outlook, By Treatment Type (2024-2032) ($MN)
  • Table 3 Global Adrenal Crisis Management Market Outlook, By Glucocorticoid Therapy (2024-2032) ($MN)
  • Table 4 Global Adrenal Crisis Management Market Outlook, By Hydrocortisone (IV/IM) (2024-2032) ($MN)
  • Table 5 Global Adrenal Crisis Management Market Outlook, By Dexamethasone (2024-2032) ($MN)
  • Table 6 Global Adrenal Crisis Management Market Outlook, By Other Glucocorticoids (2024-2032) ($MN)
  • Table 7 Global Adrenal Crisis Management Market Outlook, By Mineralocorticoid Therapy (Fludrocortisone) (2024-2032) ($MN)
  • Table 8 Global Adrenal Crisis Management Market Outlook, By Fluid & Electrolyte Replacement Therapy (2024-2032) ($MN)
  • Table 9 Global Adrenal Crisis Management Market Outlook, By Adjunctive Therapies (2024-2032) ($MN)
  • Table 10 Global Adrenal Crisis Management Market Outlook, By Route of Administration (2024-2032) ($MN)
  • Table 11 Global Adrenal Crisis Management Market Outlook, By Intravenous (IV) (2024-2032) ($MN)
  • Table 12 Global Adrenal Crisis Management Market Outlook, By Intramuscular (IM) (2024-2032) ($MN)
  • Table 13 Global Adrenal Crisis Management Market Outlook, By Oral (2024-2032) ($MN)
  • Table 14 Global Adrenal Crisis Management Market Outlook, By Subcutaneous (2024-2032) ($MN)
  • Table 15 Global Adrenal Crisis Management Market Outlook, By Patient Group (2024-2032) ($MN)
  • Table 16 Global Adrenal Crisis Management Market Outlook, By Adults (2024-2032) ($MN)
  • Table 17 Global Adrenal Crisis Management Market Outlook, By Pediatrics (2024-2032) ($MN)
  • Table 18 Global Adrenal Crisis Management Market Outlook, By Geriatrics (2024-2032) ($MN)
  • Table 19 Global Adrenal Crisis Management Market Outlook, By Neonates (2024-2032) ($MN)
  • Table 20 Global Adrenal Crisis Management Market Outlook, By Distribution Channel (2024-2032) ($MN)
  • Table 21 Global Adrenal Crisis Management Market Outlook, By Hospital Pharmacies (2024-2032) ($MN)
  • Table 22 Global Adrenal Crisis Management Market Outlook, By Retail Pharmacies (2024-2032) ($MN)
  • Table 23 Global Adrenal Crisis Management Market Outlook, By Online Pharmacies (2024-2032) ($MN)
  • Table 24 Global Adrenal Crisis Management Market Outlook, By Specialty Drug Distributors (2024-2032) ($MN)
  • Table 25 Global Adrenal Crisis Management Market Outlook, By End User (2024-2032) ($MN)
  • Table 26 Global Adrenal Crisis Management Market Outlook, By Hospitals (2024-2032) ($MN)
  • Table 27 Global Adrenal Crisis Management Market Outlook, By Emergency Care Centers (2024-2032) ($MN)
  • Table 28 Global Adrenal Crisis Management Market Outlook, By Specialty Clinics (2024-2032) ($MN)
  • Table 29 Global Adrenal Crisis Management Market Outlook, By Home Care Settings (2024-2032) ($MN)
  • Table 30 Global Adrenal Crisis Management Market Outlook, By Ambulatory Surgical Centers (2024-2032) ($MN)
  • Table 31 Global Adrenal Crisis Management Market Outlook, By Other End Users (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.